Eton Pharmaceuticals (ETON) announced the submission of a NDA to the U.S. FDA for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals management to meet virtually with B. Riley
- Eton Pharmaceuticals management to meet with Craig Hallum
- Eton Pharmaceuticals out-licenses international rights to Increlex
- Eton Pharmaceuticals price target raised to $24 from $21 at B. Riley
- Eton Pharmaceuticals price target raised to $26 from $23 at Craig-Hallum